Immatics NV (IMTX)

NASDAQ
13.15
-0.51(-3.73%)
After Hours
13.00
-0.15(-1.14%)
- Real-time Data
  • Volume:
    73,212
  • Bid/Ask:
    12.33/15.00
  • Day's Range:
    13.05 - 13.89

IMTX Overview

Prev. Close
13.66
Day's Range
13.05-13.89
Revenue
45.6M
Open
13.61
52 wk Range
9.58-18.28
EPS
-4.58
Volume
73,212
Market Cap
827.25M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
113,205
P/E Ratio
-
Beta
-
1-Year Change
29.81%
Shares Outstanding
62,908,617
Next Earnings Date
Dec 08, 2021
What is your sentiment on Immatics NV?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellSellStrong Buy

Immatics NV Company Profile

Immatics NV Company Profile

Employees
142

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company’s TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.